Product image of Metformina + Sitagliptina Pharmazac 50 Mg/1000 Mg (Metformin, Sitagliptin) supplied by GNH India

Metformina + Sitagliptina Pharmazac 50 Mg/1000 Mg

Active Ingredient:
Metformin, Sitagliptin
Origin:
EU

Metformina + Sitagliptina Pharmazac 50 Mg/1000 Mg (Metformin, Sitagliptin)

Metformin, the active ingredient in Metformina + Sitagliptina Pharmazac 50 Mg/1000 Mg, is a biguanide presented as a 1000 mg/50 mg tablet for oral use. It helps control blood glucose levels in adults with type 2 diabetes mellitus, often in combination with other antidiabetic agents to achieve glycemic targets.

GNH India supplies Metformina + Sitagliptina Pharmazac 50 Mg/1000 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and research institutions, ensuring consistent quality and regulatory compliance across markets.

Manufacturer / TM Owner

Pharmazac Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformina + Sitagliptina Pharmazac is indicated for management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

  • Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose.
  • Inadequate response to metformin alone: provides additional glucose reduction through DPP‑4 inhibition.
  • Combination therapy with diet and exercise: assists in achieving target HbA1c when lifestyle measures are insufficient.

How It Works

  • Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while sitagliptin inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, prolonging endogenous incretin activity and promoting glucose‑dependent insulin secretion, together producing additive reductions in blood glucose levels.

Side Effects

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: frequent loose stools, usually transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild tension‑type headaches.
  • Upper respiratory infection: nasopharyngitis symptoms.
  • Hypoglycemia (when combined with insulin or sulfonylureas): dizziness or sweating.

Serious or Rare Side Effects

  • Lactic acidosis: rare but life‑threatening metabolic disturbance.
  • Pancreatitis: severe abdominal pain with elevated enzymes.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic failure: jaundice, elevated liver enzymes.
  • Renal impairment: worsening kidney function, especially with dehydration.

Precautions & Warnings

Before initiating therapy, evaluate renal and hepatic function and consider patient‑specific risk factors.

  • Renal function: assess eGFR and monitor periodically.
  • Lactic acidosis risk: avoid in patients with significant renal or hepatic impairment.
  • Hypoglycemia: monitor closely when used with insulin or sulfonylureas.
  • Pregnancy and lactation: use only if benefits outweigh potential risks.
  • Cardiovascular status: exercise caution in patients with heart failure.
  • Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture.

Avoid Interactions

Metformina + Sitagliptina Pharmazac may interact with several medicines; review patient medication lists regularly.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of hypoglycemia.
  • Iodinated contrast media: potential renal dysfunction with metformin.
  • Cimetidine: may raise metformin plasma levels.
  • Strong CYP3A4 inhibitors: can increase sitagliptin exposure.
  • Alcohol abuse: heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal clearance of metformin.
  • ACE inhibitors/ARBs: monitor renal function and electrolytes.
  • Rifampin: may reduce sitagliptin concentrations.
  • Beta‑blockers: may mask hypoglycemia symptoms.
  • Thiazolidinediones: additive risk of fluid retention.

Frequently Asked Questions

Metformina + Sitagliptina Pharmazac is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It combines metformin, which lowers hepatic glucose production, with sitagliptin, which enhances insulin secretion in response to meals, providing a complementary approach to achieve target glycemic levels.

Metformin belongs to the biguanide class and primarily reduces hepatic gluconeogenesis while increasing peripheral insulin sensitivity. By decreasing the amount of glucose produced by the liver and improving muscle uptake of glucose, it helps lower fasting blood sugar and contributes to overall glycemic control.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on individual patient factors such as renal function, concomitant medications, and glycemic targets. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety in pregnancy and lactation has not been fully established. The product should only be used if the potential benefits outweigh any possible risks to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with using metformin alone, the addition of sitagliptin offers greater post‑prandial glucose reduction without the weight gain associated with some other classes, such as sulfonylureas. Unlike SGLT2 inhibitors, it does not increase the risk of genital infections, but it lacks the cardiovascular benefits seen with certain SGLT2 agents.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container to protect from moisture and light. Do not store in a humid environment or expose to excessive heat, as this may affect tablet integrity.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and not crush or split the tablets unless instructed.

The most serious adverse events include lactic acidosis, a rare but potentially fatal condition linked to metformin, and pancreatitis, which can occur with sitagliptin. Patients should seek immediate medical attention for symptoms such as severe abdominal pain, unexplained weakness, rapid breathing, or sudden onset of vomiting.

The combination is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, acute or chronic metabolic acidosis, and those with a history of lactic acidosis. It should also be avoided in individuals with severe hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT